A study in healthy men to test how well different doses of BI 3821001 are tolerated

2025-523899-23-00 Protocol 2007-0001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 15 Apr 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol 2007-0001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 72
Countries 1
Sites 1

Healthy volunteer trial

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Not possible to specify
Trial duration
15 Apr 2026 → ongoing
Decision date (initial)
2026-03-18
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-523899-23-00
WHO UTN
U1111-1328-2339

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteer trial

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 72 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruiting
CRS Clinical Research Services Berlin GmbH
Clinical Pharmacology Unit, Siemensdamm 65, Siemensstadt, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2026-04-15 2026-04-22

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-01-23 Germany Acceptable
2026-03-18
2026-03-18